NYSE:JEF
NYSE:JEFCapital Markets

Is Jefferies Still Attractive After Its Recent Rally and Advisory Pivot?

If you are wondering whether Jefferies Financial Group is still a smart buy after its big multi year run, or if the value case has already played out, you are not alone. This breakdown is here to unpack exactly that question. The stock has climbed 2.8% over the last week and 15.8% over the past month, but that sits against a softer backdrop of a -19.9% return year to date and -16.1% over the last year, even after an impressive 106.9% 3 year and 217.6% 5 year performance. Recent headlines...
NYSE:CTRE
NYSE:CTREHealth Care REITs

How Investors May Respond To CareTrust REIT (CTRE) New LTIP Units and Texas Senior Housing Deal

Earlier this month, CareTrust REIT, Inc. declared a quarterly common stock cash dividend of US$0.335 per share, payable on or about January 15, 2026 to shareholders of record as of December 31, 2025, and also amended its Operating Partnership Agreement to introduce a new class of LTIP Units for service providers. The creation of LTIP Units and the acquisition of three Texas senior living communities point to a focus on aligning employee incentives with long-term growth in seniors housing and...
NYSE:MOS
NYSE:MOSChemicals

Is Mosaic (MOS) Undervalued After Its Recent Pullback? A Fresh Look at the Fertilizer Producer’s Valuation

Mosaic (MOS) has been drifting without a headline catalyst lately, but the stock’s recent pullback and choppy performance over the past month and past 3 months are starting to catch value oriented investors’ attention. See our latest analysis for Mosaic. Zooming out, Mosaic’s longer slide is more telling. A 90 day share price return of minus 28.41 percent and a three year total shareholder return of minus 41.26 percent signal fading momentum, despite a modestly positive one year total...
NYSE:UNM
NYSE:UNMInsurance

Is It Too Late To Consider Unum Group After Its 320% Five Year Surge?

Wondering if Unum Group at around $78.69 is still a smart buy after such a big multi year run, or if most of the easy gains are already behind it? You are not alone, and that is exactly what we are going to unpack here. The stock has kept grinding higher, up 2.0% over the last week, 4.0% over the past month, 7.9% year to date, 10.6% over 1 year, a hefty 108.2% over 3 years, and an impressive 320.3% over 5 years, signaling that investors have been steadily re rating the story. Recent...
NasdaqGM:SOUN
NasdaqGM:SOUNSoftware

SoundHound AI (SOUN): Reassessing a Premium-Valued Stock After Recent Share Price Volatility

SoundHound AI (SOUN) has had a choppy run lately, with the stock roughly flat over the past month but still down sharply over the past 3 months, which naturally raises valuation questions. See our latest analysis for SoundHound AI. At the current share price of $11.27, SoundHound AI’s 90 day share price return of negative 37.6 percent and one year total shareholder return of negative 44.8 percent suggest fading momentum after an earlier speculative surge, even as investors still weigh its...
NYSE:EMR
NYSE:EMRElectrical

Is Emerson Electric Still Attractive After Automation Pivot And 89% Five Year Share Price Surge

If you have been wondering whether Emerson Electric at around $134.99 is still a buy or if the value is already priced in, you are not alone. This article is written with that exact question in mind. The stock has climbed 0.7% over the last week, 5.3% over the past month, and is up 10.5% year to date, building on an 89.0% gain over five years that has reshaped how investors think about its risk and growth profile. Recent headlines have focused on Emerson doubling down on higher margin...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Do Ardelyx’s (ARDX) Leadership Changes Reframe How Investors View Its Long-Term Pipeline Strategy?

Ardelyx, Inc. has announced that Chief Legal and Administrative Officer Elizabeth Grammer and Chief Medical Officer Edward Conner resigned effective December 31, 2025, with Grammer transitioning to General Counsel and then Senior Advisor, and Chief Patient Officer Laura Williams stepping in as interim Chief Medical Officer. These leadership shifts, with Grammer remaining in advisory roles and Williams temporarily overseeing clinical development, raise questions about continuity in legal,...
NasdaqCM:NUTX
NasdaqCM:NUTXHealthcare

Nutex Health (NUTX): Valuation Check After New St. Louis Hospital Expands Its Micro Hospital Network

Nutex Health (NUTX) just opened its 26th hospital, and first in Missouri, with the new Archview ER & Hospital in St. Louis, a move that quietly extends its micro hospital footprint into a fresh urban market. See our latest analysis for Nutex Health. That backdrop helps explain why sentiment has heated up, with Nutex Health’s 30 day share price return of 31.14 percent feeding into a powerful 417.14 percent year to date share price surge, even as its three year total shareholder return remains...